Oragenics, Inc.

OGEN

$0.50

-1.50%

N/A-$0.01

Healthcare

Biotechnology

AMEX

Active Trading

Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two ...

Insider Transactions of OGEN

Acquisitions (A)

Since Dec 11, 2025

Disposals (D)

Since Dec 11, 2025

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jul 1, 2026	Spencer John	officer: Chief Financial Officer	Employee Stock Option (right to buy)	A	55,900	$0.59
Jul 1, 2026	Spencer John	officer: Chief Financial Officer	Common Stock	—	0	—
Jul 1, 2026	Spencer John	officer: Chief Financial Officer	Employee Stock Option (right to buy)	—	10,000	$0.93
Dec 12, 2025	Telling Fred	director	Common Stock	D	210	$0.94
Dec 12, 2025	Telling Fred	director	Common Stock	D	210	$0.94

Insider Trading Snapshot

Acquisitions (A)

Disposals (D)

Total Shares Bought

719,220

Total Shares Sold

420

Monthly Insider Activity

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Transactions by Title - Shares

X-axis: shares, sorted by total shares desc

Transactions by Title - Counts

X-axis: counts, sorted by A+D counts desc

Key People: Buy/Sell Activity and Price

Huffman Janet

officer: CEO and CFO • 1 txns

Spencer John

officer: Chief Financial Officer • 3 txns

Telling Fred

director • 3 txns

Giordano Natasha

director • 2 txns

Transactions Table

Date	Executive	Title	Security	Side	Shares	Price	Value
Jul 1, 2026	Spencer John	officer: Chief Financial Officer	Employee Stock Option (right to buy)	A	55,900	$0.59	$32,981.00
Jul 1, 2026	Spencer John	officer: Chief Financial Officer	Common Stock	—	0	—	—
Jul 1, 2026	Spencer John	officer: Chief Financial Officer	Employee Stock Option (right to buy)	—	10,000	$0.93	$9,300.00
Dec 12, 2025	Telling Fred	director	Common Stock	D	210	$0.94	$198.37
Dec 12, 2025	Telling Fred	director	Common Stock	D	210	$0.94	$198.37
Dec 11, 2025	Huffman Janet	officer: CEO and CFO	Employee Stock Option (right to buy)	A	250,000	$0.93	$232,500.00
Dec 11, 2025	Giordano Natasha	director	Non-Employee Director Option (Right to Buy)	A	125,000	$0.93	$116,250.00
Dec 11, 2025	Giordano Natasha	director	Non-Employee Director Option (Right to Buy)	A	38,320	$1.03	$39,469.60
Dec 11, 2025	Telling Fred	director	Non-Employee Director Option (Right to Buy)	A	125,000	$0.93	$116,250.00
Dec 11, 2025	GANDOLFO JOHN P	director	Non-Employee Director Option (Right to Buy)	A	125,000	$0.93	$116,250.00

Supply Chain of OGEN

RELATIONS

Upstream

Sterling Pharma SolutionsAvance ClinicalSouthern Star ResearchKBI BiopharmaBiodextrisReceptor.AIDuck Flats PharmaEKF Diagnostics Holdings plcLON:EKFJSR CorporationGHO Capital

Downstream

BRAINBox Solutions, Inc.Inspirevax

Proxies

Precigen, Inc. (f/k/a Intrexon Corporation)NASDAQ:PGENEKF Diagnostics Holdings plcLON:EKF

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer